Is there a new treatment for lung cancer?
Patients in the United States with a rare and serious form of lung cancer will be the first to receive a new drug to treat lung cancer, and trials of the pill-based treatment, mobocertinib, have shown that it saves patients an additional two years of life.
About 100 patients with an advanced form of lung cancer - which is driven by mutations and cannot be treated surgically - will be eligible for the drug each year after undergoing chemotherapy. This type of cancer mainly affects young people and non-smokers.
This treatment reduces the bet of death by 40% by the age of two and by 37% the gamble of early recurrence of malignant growth, this is a confidential report. Cellular breakdown in the lungs is the leading source of death from lung cancer in the USA.
The third phase of the study called CheckMate 816 was published on Monday, with the findings that should "change practices" in the management of this cancer, particularly the early stages, according to Pr Christine M. Lovely, an oncologist at Vanderbilt University (USA).
The study of 358 patients showed that the combination of conventional chemotherapy and immunotherapy, before surgery, significantly reduces the risk of death and recurrence. For this, the tumor must be well localized, operable, and free of infiltration.
Does this new treatment for the secret of the secret reduce the risk of death by 40%?
If immunotherapy does indeed help slow the progression of metastatic cancers, it is now proving effective in earlier cancers. Combining preoperative immunotherapy and chemotherapy reduced the risk of death at age 2 years by 40% and the risk of recurrence by 37%. In addition, in a quarter of patients, the tumor becomes noncancerous after treatment. By comparison, this number drops to 2% after chemotherapy alone.
survival without disease recurrence or progression is 31.6 months with this dual therapy, compared to 20.8 months with chemotherapy alone. Within two years, 63.8% of patients in the first group had not seen a return of the disease, compared to 45.3% in the placebo group.
The new treatment for lung cancer is already licensed in the USA
This treatment consists of a combination of three sessions of immunotherapy, immune system strengthening, and chemotherapy, and therefore has the advantage of being relatively short: two months in total. Thus, the burden of treatment for the patient and its cost to society are also reduced. However, the key to success is to detect the disease at an early stage in as many patients as possible.
Even before the study was published, this new, novel treatment had received clearance from the US Federal Health Agency (FDA) for use in the United States.
Comments
Post a Comment